9 research outputs found
Clot-Targeted Micellar Formulation Improves Anticoagulation Efficacy of Bivalirudin
Application of anticoagulants remains the primary strategy for prevention and treatment of thrombosis. However, high rate of bleeding complications limits their use. The peptide anticoagulant bivalirudin has been reported to exhibit a lower rate of bleeding complications than heparin, and it also has the advantage of not causing thrombocytopenia, which is a problem with heparin. Nonetheless, hemorrhage is the most common complication of bivalirudin therapy, and there is no effective antidote. Here we use a thrombus-binding peptide, CR(<i>N</i>Me)EKA, to accomplish selective delivery of the bivalirudin-carrying micellar nanocarrier to sites of thrombosis. Bivalirudin and CR(<i>N</i>Me)EKA, each with a PEG-lipid tail, spontaneously assembled into 30 nm micelles, which almost completely retained the anticoagulant activity of bivalirudin. The micellar formulations exhibited high stability both <i>in vitro</i> and <i>in vivo</i>. In a thromboplastin-induced mouse thrombosis model, the targeted micelles accumulated in lung thrombi 10-fold more than nontargeted micelles. Moreover, the micellar formulation significantly prolonged the half-life and thereby increased the bioavailability of bivalirudin. The micellar bivalirudin had significantly higher anticoagulant activity than free bivalirudin in both the lung thrombosis model and a ferric chloride-induced carotid artery thrombosis model. The specific targeting of thrombi demonstrated here makes it possible to increase the efficacy of bivalirudin as an anticoagulant. Alternatively, the dose could be reduced without loss of efficacy to lower the systemic exposure and improve safety
Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth
Antiangiogenic
and vascular disrupting compounds have shown promise
in cancer therapy, but tend to be only partially effective. We previously
reported a potent theranostic nanosystem that was highly effective
in glioblastoma and breast cancer mouse models, retarding tumor growth
and producing some cures [Agemy, L. et
al. Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 17450â17455. Agemy, L. et
al. Mol. Ther. 2013, 21, 2195â2204.]. The nanosystem consists of iron oxide NPs (ânanowormsâ)
coated with a composite peptide with tumor-homing and pro-apoptotic
domains. The homing component targets tumor vessels by binding to
p32/gC1qR at the surface or tumor endothelial cells. We sought to
further improve the efficacy nanosystem by searching for an optimally
effective homing peptide that would also incorporate a tumor-penetrating
function. To this effect, we tested a panel of candidate p32 binding
peptides with a sequence motif that conveys tumor-penetrating activity
(CendR motif). We identified a peptide designated as Linear TT1 (Lin
TT1) (sequence: AKRÂGARÂSTA) as most effective in causing
tumor homing and penetration of the nanosystem. This peptide had the
lowest affinity for p32 among the peptides tested. The low affinity
may have moderated the avidity effect from the multivalent presentation
on nanoparticles (NPs), such that the NPs avoid getting trapped by
the so-called âbinding-site barrierâ, which can hinder
tissue penetration of compounds with a high affinity for their receptors.
Treatment of breast cancer mice with the LinTT1 nanosystem showed
greatly improved efficacy compared to the original system. These results
identify a promising treatment modality and underscore the value of
tumor penetration effect in improving the efficacy tumor treatment
Composite Porous SiliconâSilver Nanoparticles as Theranostic Antibacterial Agents
A theranostic
nanoparticle with biochemically triggered antibacterial
activity is demonstrated. Metallic silver is deposited onto porous
silicon nanoparticles (pSiNPs) by galvanic displacement. When aqueous
diaminesilver ([AgÂ(NH<sub>3</sub>)<sub>2</sub>]<sup>+</sup>) is used
as a silver source, the pSiNPs template the crystalline silver as
small (mean diameter 13 nm) and well-dispersed nanoparticles embedded
within and on the larger (100 nm) pSiNPs. The silver nanoparticles
(AgNPs) quench intrinsic photoluminescence (PL) from the porous silicon
(pSi) matrix. When exposed to an aqueous oxidant, the AgNPs are preferentially
etched, Ag<sup>+</sup> is released into solution, and PL from the
pSi carrier is recovered. The released Ag<sup>+</sup> results in 90%
killing of (Gram-negative) <i>Pseudomonas aeruginosa</i> and (Gram-positive) <i>Staphylococcus aureus</i> within
3 h. When conjugated with the TAT peptide (sequence RKKRRQRRR), the
silver-deposited porous silicon (pSi-Ag) nanocomposite shows distinct
targeting toward <i>S. aureus</i> bacteria in vitro. Intravenously
injected TAT-conjugated pSi-Ag nanoparticles accumulate in the liver,
spleen, and lungs of mice, and the in vivo release of Ag<sup>+</sup> and recovery of PL from pSi are demonstrated by the subsequent intraperitoneal
administration of a hexacyanoferrate solution. The released Ag<sup>+</sup> leads to a significant bacterial count reduction in liver
tissue relative to the control. The data demonstrate the feasibility
of the targeted and triggered delivery of antibacterial Ag<sup>+</sup> ion in vivo, using a self-reporting and nontoxic nanocarrier
Different Effect of Hydrogelation on Antifouling and Circulation Properties of DextranâIron Oxide Nanoparticles
Premature recognition and clearance of nanoparticulate
imaging
and therapeutic agents by macrophages in the tissues can dramatically
reduce both the nanoparticle half-life and delivery to the diseased
tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate
recognition by liver and spleen macrophages and greatly prolongs circulation
times in vivo. Understanding the mechanisms by which hydrogels achieve
this âstealthâ effect has implications for the design
of long-circulating nanoparticles. Thus, the role of plasma protein
absorption in the hydrogel effect is not yet understood. Short-circulating
dextran-coated iron oxide nanoparticles could be converted into stealth
hydrogel nanoparticles by cross-linking with 1-chloro-2,3-epoxypropane.
We show that hydrogelation did not affect the size, shape and zeta
potential, but completely prevented the recognition and clearance
by liver macrophages <i>in vivo</i>. Hydrogelation decreased
the number of hydroxyl groups on the nanoparticle surface and reduced
the binding of the anti-dextran antibody. At the same time, hydrogelation
did not reduce the absorption of cationic proteins on the nanoparticle
surface. Specifically, there was no effect on the binding of kininogen,
histidine-rich glycoprotein, and protamine sulfate to the anionic
nanoparticle surface. In addition, hydrogelation did not prevent activation
of plasma kallikrein on the metal oxide surface. These data suggest
that (a) a stealth hydrogel coating does not mask charge interactions
with iron oxide surface and (b) the total blockade of plasma protein
absorption is not required for maintaining iron oxide nanoparticlesâ
long-circulating stealth properties. These data illustrate a novel,
clinically promising property of long-circulating stealth nanoparticles
<sup>64</sup>Cu-Labeled LyPâ1-Dendrimer for PET-CT Imaging of Atherosclerotic Plaque
The ability to detect and quantify
macrophage accumulation can
provide important diagnostic and prognostic information for atherosclerotic
plaque. We have previously shown that LyP-1, a cyclic 9-amino acid
peptide, binds to p32 proteins on activated macrophages, facilitating
the visualization of atherosclerotic plaque with PET. Yet, the in
vivo plaque accumulation of monomeric [<sup>18</sup>F]ÂFBA-LyP-1 was
low (0.31 ± 0.05%ID/g). To increase the avidity of LyP-1 constructs
to p32, we synthesized a dendritic form of LyP-1 on solid phase using
lysine as the core structural element. Imaging probes (FAM or 6-BAT)
were conjugated to a lysine or cysteine on the dendrimer for optical
and PET studies. The N-terminus of the dendrimer was further modified
with an aminooxy group in order to conjugate LyP-1 and ARAL peptides
bearing a ketone. Oxime ligation of peptides to both dendrimers resulted
in (LyP-1)<sub>4</sub>- and (ARAL)<sub>4</sub>-dendrimers with optical
(FAM) and PET probes (6-BAT). For PET-CT studies, (LyP-1)<sub>4</sub>- and (ARAL)<sub>4</sub>-dendrimer-6-BAT were labeled with <sup>64</sup>Cu (<i>t</i><sub>1/2</sub> = 12.7 h) and intravenously
injected into the atherosclerotic (ApoE<sup>â/â</sup>) mice. After two hours of circulation, PET-CT coregistered images
demonstrated greater uptake of the (LyP-1)<sub>4</sub>-dendrimer-<sup>64</sup>Cu than the (ARAL)<sub>4</sub>-dendrimer-<sup>64</sup>Cu
in the aortic root and descending aorta. Ex vivo images and the biodistribution
acquired at three hours after injection also demonstrated a significantly
higher uptake of the (LyP-1)<sub>4</sub>-dendrimer-<sup>64</sup>Cu
(1.1 ± 0.26%ID/g) than the (ARAL)<sub>4</sub>-dendrimer-<sup>64</sup>Cu (0.22 ± 0.05%ID/g) in the aorta. Similarly, subcutaneous
injection of the LyP-1-dendrimeric carriers resulted in preferential
accumulation in plaque-containing regions over 24 h. In the same model
system, ex vivo fluorescence images within aortic plaque depict an
increased accumulation and penetration of the (LyP-1)<sub>4</sub>-dendrimer-FAM
as compared to the (ARAL)<sub>4</sub>-dendrimer-FAM. Taken together,
the results suggest that the (LyP-1)<sub>4</sub>-dendrimer can be
applied for in vivo PET imaging of plaque and that LyP-1 could be
further exploited for the delivery of therapeutics with multivalent
carriers or nanoparticles
Different Effect of Hydrogelation on Antifouling and Circulation Properties of DextranâIron Oxide Nanoparticles
Premature recognition and clearance of nanoparticulate
imaging
and therapeutic agents by macrophages in the tissues can dramatically
reduce both the nanoparticle half-life and delivery to the diseased
tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate
recognition by liver and spleen macrophages and greatly prolongs circulation
times in vivo. Understanding the mechanisms by which hydrogels achieve
this âstealthâ effect has implications for the design
of long-circulating nanoparticles. Thus, the role of plasma protein
absorption in the hydrogel effect is not yet understood. Short-circulating
dextran-coated iron oxide nanoparticles could be converted into stealth
hydrogel nanoparticles by cross-linking with 1-chloro-2,3-epoxypropane.
We show that hydrogelation did not affect the size, shape and zeta
potential, but completely prevented the recognition and clearance
by liver macrophages <i>in vivo</i>. Hydrogelation decreased
the number of hydroxyl groups on the nanoparticle surface and reduced
the binding of the anti-dextran antibody. At the same time, hydrogelation
did not reduce the absorption of cationic proteins on the nanoparticle
surface. Specifically, there was no effect on the binding of kininogen,
histidine-rich glycoprotein, and protamine sulfate to the anionic
nanoparticle surface. In addition, hydrogelation did not prevent activation
of plasma kallikrein on the metal oxide surface. These data suggest
that (a) a stealth hydrogel coating does not mask charge interactions
with iron oxide surface and (b) the total blockade of plasma protein
absorption is not required for maintaining iron oxide nanoparticlesâ
long-circulating stealth properties. These data illustrate a novel,
clinically promising property of long-circulating stealth nanoparticles
Different Effect of Hydrogelation on Antifouling and Circulation Properties of DextranâIron Oxide Nanoparticles
Premature recognition and clearance of nanoparticulate
imaging
and therapeutic agents by macrophages in the tissues can dramatically
reduce both the nanoparticle half-life and delivery to the diseased
tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate
recognition by liver and spleen macrophages and greatly prolongs circulation
times in vivo. Understanding the mechanisms by which hydrogels achieve
this âstealthâ effect has implications for the design
of long-circulating nanoparticles. Thus, the role of plasma protein
absorption in the hydrogel effect is not yet understood. Short-circulating
dextran-coated iron oxide nanoparticles could be converted into stealth
hydrogel nanoparticles by cross-linking with 1-chloro-2,3-epoxypropane.
We show that hydrogelation did not affect the size, shape and zeta
potential, but completely prevented the recognition and clearance
by liver macrophages <i>in vivo</i>. Hydrogelation decreased
the number of hydroxyl groups on the nanoparticle surface and reduced
the binding of the anti-dextran antibody. At the same time, hydrogelation
did not reduce the absorption of cationic proteins on the nanoparticle
surface. Specifically, there was no effect on the binding of kininogen,
histidine-rich glycoprotein, and protamine sulfate to the anionic
nanoparticle surface. In addition, hydrogelation did not prevent activation
of plasma kallikrein on the metal oxide surface. These data suggest
that (a) a stealth hydrogel coating does not mask charge interactions
with iron oxide surface and (b) the total blockade of plasma protein
absorption is not required for maintaining iron oxide nanoparticlesâ
long-circulating stealth properties. These data illustrate a novel,
clinically promising property of long-circulating stealth nanoparticles
Different Effect of Hydrogelation on Antifouling and Circulation Properties of DextranâIron Oxide Nanoparticles
Premature recognition and clearance of nanoparticulate
imaging
and therapeutic agents by macrophages in the tissues can dramatically
reduce both the nanoparticle half-life and delivery to the diseased
tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate
recognition by liver and spleen macrophages and greatly prolongs circulation
times in vivo. Understanding the mechanisms by which hydrogels achieve
this âstealthâ effect has implications for the design
of long-circulating nanoparticles. Thus, the role of plasma protein
absorption in the hydrogel effect is not yet understood. Short-circulating
dextran-coated iron oxide nanoparticles could be converted into stealth
hydrogel nanoparticles by cross-linking with 1-chloro-2,3-epoxypropane.
We show that hydrogelation did not affect the size, shape and zeta
potential, but completely prevented the recognition and clearance
by liver macrophages <i>in vivo</i>. Hydrogelation decreased
the number of hydroxyl groups on the nanoparticle surface and reduced
the binding of the anti-dextran antibody. At the same time, hydrogelation
did not reduce the absorption of cationic proteins on the nanoparticle
surface. Specifically, there was no effect on the binding of kininogen,
histidine-rich glycoprotein, and protamine sulfate to the anionic
nanoparticle surface. In addition, hydrogelation did not prevent activation
of plasma kallikrein on the metal oxide surface. These data suggest
that (a) a stealth hydrogel coating does not mask charge interactions
with iron oxide surface and (b) the total blockade of plasma protein
absorption is not required for maintaining iron oxide nanoparticlesâ
long-circulating stealth properties. These data illustrate a novel,
clinically promising property of long-circulating stealth nanoparticles
Recognition of DextranâSuperparamagnetic Iron Oxide Nanoparticle Conjugates (Feridex) via Macrophage Scavenger Receptor Charged Domains
Dextran-coated superparamagnetic iron oxide nanoparticles
(dextranâSPIO
conjugates) offer the attractive possibility of enhancing MRI imaging
sensitivity so that small or diffuse lesions can be detected. However,
systemically injected SPIOs are rapidly removed by macrophages. We
engineered embryonic cells (HEK293T) to express major macrophage scavenger
receptor (SR) subtypes including SR-AI, MARCO, and endothelial receptor
collectin-12. These SRs possess a positively charged collagen-like
(CL) domain and they promoted SPIO uptake, while the charge neutral
lipoprotein receptor SR-BI did not. In silico modeling indicated a
positive net charge on the CL domain and a net negative charge on
the cysteine-rich (CR) domain of MARCO and SR-AI. In vitro experiments
revealed that CR domain deletion in SR-AI boosted uptake of SPIO 3-fold,
while deletion of MARCOâs CR domain abolished this uptake.
These data suggest that future studies might productively focus on
the validation and further exploration of SR charge fields in SPIO
recognition